A rational surgical approach to the treatment of distant melanoma metastases

Cancer Treatment Reviews

Volumn 34, Issue 7, 2008, Pages 614-620

  Martinez, Steve R ^a   Young, Shawn E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Surgical Consultants PC   (United States)

Author keywords

Chemotherapy; Distant metastasis; Melanoma; Metastasectomy; Resection; Surgery

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; CARMUSTINE; CISPLATIN; CONTRAST MEDIUM; DACARBAZINE; FLUORODEOXYGLUCOSE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; ONAMELATEUCIL; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ADJUVANT THERAPY; ADVANCED CANCER; BONE METASTASIS; BRAIN METASTASIS; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CRYOSURGERY; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; ECHOGRAPHY; FUNCTIONAL STATUS; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LIVER SURGERY; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC SURGERY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PROGNOSIS; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SOFT TISSUE METASTASIS; STEREOTAXIC SURGERY; SURGICAL APPROACH; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISCERAL METASTASIS;

BONE NEOPLASMS; BRAIN NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 53849103584     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.05.003     Document Type: Review

References (83)

1. Balch C.M., Soong S.J., Atkins M.B., et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54 3 (2004) 131-149 [quiz 82-4]
2. Bafaloukos D., Tsoutsos D., Fountzilas G., et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res 14 4 (2004) 289-294
3. Berdeaux D.H., Moon T.E., and Meyskens Jr. F.L. Clinical-biologic patterns of metastatic melanoma and their effect on treatment. Cancer Treat Rep 69 4 (1985) 397-401
4. Chapman P.B., Einhorn L.H., Meyers M.L., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17 9 (1999) 2745-2751
5. Emmert S., Zutt M., Haenssle H., Neumann C., and Kretschmer L. Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents. Melanoma Res 13 3 (2003) 299-302
6. Fink W., Zimpfer-Rechner C., Thoelke A., et al. Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie 27 6 (2004) 540-544
7. Hwu W.J., Krown S.E., Menell J.H., et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21 17 (2003) 3351-3356
8. Legha S.S., Ring S., Papadopoulos N., Plager C., Chawla S., and Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64 10 (1989) 2024-2029
9. McClay E.F., Mastrangelo M.J., Berd D., and Bellet R.E. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 50 4 (1992) 553-556
10. Neuber K., Reinhold U., Deutschmann A., et al. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. Melanoma Res 13 1 (2003) 81-85
11. Presant C.A., and Bartolucci A.A. Prognostic factors in metastatic malignant melanoma: The Southeastern Cancer Study Group Experience. Cancer 49 10 (1982) 2192-2196
12. Robidoux A., Gutterman J.U., Bodey Sr. G.P., and Hersh E.M. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma. Cancer 49 11 (1982) 2246-2251
13. Ryan L., Kramar A., and Borden E. Prognostic factors in metastatic melanoma. Cancer 71 10 (1993) 2995-3005
14. Whitehead R.P., Moon J., McCachren S.S., et al. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer 100 8 (2004) 1699-1704
15. Legha S.S. Current therapy for malignant melanoma. Semin Oncol 16 1 Suppl. 1 (1989) 34-44
16. Danson S.J., and Middleton M.R. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 1 1 (2001) 13-19
17. Middleton M.R., Grob J.J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18 1 (2000) 158-166
18. Buzaid A.C., Legha S.S., and Winn R. Cisplatin (C), cinblastine (V), and dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a Phase II Cancer Community Oncology Program (CCOP) trial. Proc Am Soc Clin Oncol 12 (1993) 389a
19. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 7 (1999) 2105-2116
20. Keilholz U., and Eggermont A.M. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program. Cancer J Sci Am 6 Suppl. 1 (2000) S99-S103
21. Keilholz U., Martus P., Punt C.J., et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 38 11 (2002) 1501-1511
22. O'Day S.J., Gammon G., Boasberg P.D., et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17 9 (1999) 2752-2761
23. Richards J.M., Gale D., Mehta N., and Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 17 2 (1999) 651-657
24. Atkins M.B., Lee S., Flaherty L.E., Sosman J.A., Sondak V.K., and Kirkwood J.M. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 22 (2003) 2847
25. Bajetta E., Del Vecchio M., Nova P., et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 17 4 (2006) 571-577
26. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20 8 (2002) 2045-2052
27. Barth A., Wanek L.A., and Morton D.L. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181 3 (1995) 193-201
28. Essner R., Lee J.H., Wanek L.A., Itakura H., and Morton D.L. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139 9 (2004) 961-966 [Discussion 6-7]
29. Morton D.L., Ollila D.W., Hsueh E.C., Essner R., and Gupta R.K. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 49 2 (1999) 101-116 65
30. Ollila D.W., Hsueh E.C., Stern S.L., and Morton D.L. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 71 4 (1999) 209-213
31. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am 83 1 (2003) 109-156
32. Allen P.J., and Coit D.G. The role of surgery for patients with metastatic melanoma. Curr Opin Oncol 14 2 (2002) 221-226
33. Morton DL. An international, randomized, double-blind, phase 3 study of the specific active immunotherapy agent, onamelatucel-L (Canvaxin), compared to placebo as a post-surgical adjuvant in AJCC stage IV melanoma. In: Proceedings of the society for surgical oncology; 2006.
34. Blum A., Schmid-Wendtner M.H., Mauss-Kiefer V., Eberle J.Y., Kuchelmeister C., and Dill-Muller D. Ultrasound mapping of lymph node and subcutaneous metastases in patients with cutaneous melanoma: results of a prospective multicenter study. Dermatology 212 1 (2006) 47-52
35. Muller-Horvat C., Radny P., Eigentler T.K., et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer 42 3 (2006) 342-350
36. Pfannenberg C., Aschoff P., Schanz S., et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 43 3 (2007) 557-564
37. Falk M.S., Truitt A.K., Coakley F.V., Kashani-Sabet M., Hawkins R.A., and Franc B. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma. Nucl Med Commun 28 4 (2007) 273-280
38. Akcali C., Zincirkeser S., Erbagcy Z., et al. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT. J Int Med Res 35 4 (2007) 547-553
39. Garbe C., Paul A., Kohler-Spath H., et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 21 3 (2003) 520-529
40. Dalrymple-Hay M.J., Rome P.D., Kennedy C., Fulham M., and McCaughan B.C. Pulmonary metastatic melanoma - the survival benefit associated with positron emission tomography scanning. Eur J Cardiothorac Surg 21 4 (2002) 611-614 [Discussion 4-5]
41. Finkelstein S.E., Carrasquillo J.A., Hoffman J.M., et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol 11 8 (2004) 731-738
42. Knorr C., Meyer T., Janssen T., Goehl J., and Hohenberger W. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. Eur J Surg Oncol 32 2 (2006) 224-227
43. Noorda E.M., Vrouenraets B.C., Nieweg O.E., van Geel A.N., Eggermont A.M., and Kroon B.B. Prognostic factors for survival after isolated limb perfusion for malignant melanoma. Eur J Surg Oncol 29 10 (2003) 916-921
44. Sanki A., Kam P.C., and Thompson J.F. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 245 4 (2007) 591-596
45. Nathanson L. Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother Rep 56 5 (1972) 659-665
46. Tan J.K., and Ho V.C. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 19 11 (1993) 985-990
47. Green D.S., Bodman-Smith M.D., Dalgleish A.G., and Fischer M.D. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 156 2 (2007) 337-345
48. Wolf I.H., Smolle J., Binder B., Cerroni L., Richtig E., and Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 139 3 (2003) 273-276
49. Leo F., Cagini L., Rocmans P., et al. Lung metastases from melanoma: when is surgical treatment warranted?. Br J Cancer 83 5 (2000) 569-572
50. Ollila D.W., and Morton D.L. Tumor doubling time and survival. J Surg Oncol 71 4 (1999) 249
51. Ollila D.W., Stern S.L., and Morton D.L. Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol 69 4 (1998) 206-211
52. Harpole Jr. D.H., Johnson C.M., Wolfe W.G., George S.L., and Seigler H.F. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 103 4 (1992) 743-748 [Discussion 8-50]
53. Gutman H., Hess K.R., Kokotsakis J.A., Ross M.I., Guinee V.F., and Balch C.M. Surgery for abdominal metastases of cutaneous melanoma. World J Surg 25 6 (2001) 750-758
54. Schuchter L.M., Green R., and Fraker D. Primary and metastatic diseases in malignant melanoma of the gastrointestinal tract. Curr Opin Oncol 12 2 (2000) 181-185
55. Panagiotou I., Brountzos E.N., Bafaloukos D., Stoupis C., Brestas P., and Kelekis D.A. Malignant melanoma metastatic to the gastrointestinal tract. Melanoma Res 12 2 (2002) 169-173
56. Wysocki W.M., Komorowski A.L., and Darasz Z. Gastrointestinal metastases from malignant melanoma: report of a case. Surg Today 34 6 (2004) 542-546
57. Wood T.F., DiFronzo L.A., Rose D.M., et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival?. Ann Surg Oncol 8 8 (2001) 658-662
58. Ollila D.W., Essner R., Wanek L.A., and Morton D.L. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 131 9 (1996) 975-979 9-80
59. Stewart W.R., Gelberman R.H., Harrelson J.M., and Seigler H.F. Skeletal metastases of melanoma. J Bone Joint Surg Am 60 5 (1978) 645-649
60. DeBoer D.K., Schwartz H.S., Thelman S., and Reynolds V.H. Heterogeneous survival rates for isolated skeletal metastases from melanoma. Clin Orthop Relat Res 323 (1996) 277-283
61. Rose D.M., Essner R., Hughes T.M., et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 136 8 (2001) 950-955
62. Gokaslan Z.L., Aladag M.A., and Ellerhorst J.A. Melanoma metastatic to the spine: a review of 133 cases. Melanoma Res 10 1 (2000) 78-80
63. Bilchik A.J., Rose D.M., Allegra D.P., Bostick P.J., Hsueh E., and Morton D.L. Radiofrequency ablation: a minimally invasive technique with multiple applications. Cancer J Sci Am 5 6 (1999) 356-361
64. Bleicher R.J., Allegra D.P., Nora D.T., Wood T.F., Foshag L.J., and Bilchik A.J. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 10 1 (2003) 52-58
65. de la Monte S.M., Moore G.W., and Hutchins G.M. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 43 7 (1983) 3427-3433
66. Patel J.K., Didolkar M.S., Pickren J.W., and Moore R.H. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135 6 (1978) 807-810
67. Madajewicz S., Karakousis C., West C.R., Caracandas J., and Avellanosa A.M. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer 53 11 (1984) 2550-2552
68. Sampson J.H., Carter Jr. J.H., Friedman A.H., and Seigler H.F. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88 1 (1998) 11-20
69. Gonzalez-Martinez J., Hernandez L., Zamorano L., et al. Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience. J Neurosurg 97 5 Suppl. (2002) 494-498
70. Bafaloukos D., and Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30 6 (2004) 515-520
71. McWilliams R.R., Brown P.D., Buckner J.C., Link M.J., and Markovic S.N. Treatment of brain metastases from melanoma. Mayo Clin Proc 78 12 (2003) 1529-1536
72. Tarhini A.A., and Agarwala S.S. Management of brain metastases in patients with melanoma. Curr Opin Oncol 16 2 (2004) 161-166
73. Saha S., Meyer M., Krementz E.T., et al. Prognostic evaluation of intracranial metastasis in malignant melanoma. Ann Surg Oncol 1 1 (1994) 38-44
74. Skibber J.M., Soong S.J., Austin L., Balch C.M., and Sawaya R.E. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3 2 (1996) 118-123
75. Ewend M.G., Carey L.A., and Brem H. Treatment of melanoma metastases in the brain. Semin Surg Oncol 12 6 (1996) 429-435
76. Patchell R.A., Tibbs P.A., Walsh J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322 8 (1990) 494-500
77. Vecht C.J., Haaxma-Reiche H., Noordijk E.M., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 33 6 (1993) 583-590
78. Broadbent A.M., Hruby G., Tin M.M., Jackson M., and Firth I. Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. Radiother Oncol 71 3 (2004) 259-265
79. Breneman J.C., Warnick R.E., Albright Jr. R.E., et al. Stereotactic radiosurgery for the treatment of brain metastases. Results of a single institution series. Cancer 79 3 (1997) 551-557
80. Chen J.C., Petrovich Z., O'Day S., et al. Stereotactic radiosurgery in the treatment of metastatic disease to the brain. Neurosurgery 47 2 (2000) 268-279 [Discussion 79-81]
81. Gaudy-Marqueste C., Regis J.M., Muracciole X., et al. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 65 3 (2006) 809-816
82. Mathieu D., Kondziolka D., Cooper P.B., et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 60 3 (2007) 471-481 [Discussion 81-2]
83. Andrews D.W., Scott C.B., Sperduto P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 9422 (2004) 1665-1672